Dov Elefant

Althera Medical Ltd. develops therapeutic devices for the treatment of various cancers. The private company is based in Bnei Braq, Israel.

Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York.

EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY.

Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.

Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom.